M&A Deal Summary

Twist Bioscience Acquires Abveris

On November 22, 2021, Twist Bioscience acquired life science company Abveris for 190M USD

Acquisition Highlights
  • This is Twist Bioscience’s 2nd transaction in the Life Science sector.
  • This is Twist Bioscience’s largest (disclosed) transaction.
  • This is Twist Bioscience’s 3rd transaction in the United States.
  • This is Twist Bioscience’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2021-11-22
Target Abveris
Sector Life Science
Buyer(s) Twist Bioscience
Deal Type Add-on Acquisition
Deal Value 190M USD
Advisor(s) Edgemont Capital Partners LP (Financial)
Nutter McClennen & Fish (Legal)

Target

Abveris

Canton, Massachusetts, United States
Abveris offers comprehensive antibody discovery and characterization services using its proprietary DiversimAb™ family of hyperimmune mouse models. Abveris was founded in 2014 and is based in Canton, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Twist Bioscience

San Francisco, California, United States
Category Company
Founded 2013
Sector Life Science
Employees919
Revenue 245M USD (2023)
DESCRIPTION

Twist Bioscience has developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality, and high throughput synthetic gene production. Twist Bioscience was founded in 2013 and is based in San Francisco, California.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 3 of 3
State (Massachusetts) 1 of 1
Country (United States) 3 of 3
Year (2021) 2 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-30 iGenomX

Carlsbad, California, United States

iGenomX company offers multiplex library preparation tools for next-generation sequencing (NGS) workflows. iGenomX develops and commercializes a high-throughput rapid library preparation that facilitates large sample volume with a simple workflow at enabling price points. The resulting commercial library construction maximizes laboratory capacity for many applications including population genetics, agrigenomics, microbiome, and synthetic biology. iGenomX was founded in 2012 and is based in Carlsbad, California.

Buy $35M
Mergr

Product

Company

Legal